Recently, the 2025 Hong Kong International Biotechnology Conference & Exhibition (BIOHK) was held in Hong Kong. Grand Pharma (0512.HK) was invited to participate in the event. At the “Biotech Leader Forum: A Dialogue with Global Leaders on the Future of Biopharma,” we shared our perspectives on the future development of the global nuclear pharmaceutical industry and introduced our strategic layout for the global expansion of its full nuclear pharmaceutical industry chain.
- Grand Pharma will build our global pharmaceutical brand through a “Go Global” strategy, leveraging our existing integrated global R&D, manufacturing, and sales capabilities. With exclusive global rights to products including Yigantai®, STC3141, and GPN02006, we will independently conduct international multi-center clinical trials, drawing on our overseas clinical research and sales expertise.
- We are committed to exploring diverse international collaboration models to integrate established market channels, enhance our products’ global market penetration and influence, and ensure our innovations truly benefit patients worldwide.
